Instrument Inactif

Communiqués ImmunoGen, Inc.

Actions

IMGN

US45253H1014

Recherche biotechnologique et médicale

Communiqués

12/02/24	AbbVie Completes Acquisition of ImmunoGen	PR
01/02/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
04/01/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
03/01/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10/12/23	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	BU
06/12/23	FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer	AQ
05/12/23	FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer	BU
05/12/23	IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN	BU
04/12/23	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
01/12/23	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
30/11/23	Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio	AQ
30/11/23	AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio	PR
02/11/23	ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference	BU
02/11/23	ImmunoGen: Q3 Earnings Snapshot	AQ
02/11/23	ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results	BU
01/11/23	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
30/10/23	ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer	AQ
27/10/23	ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer	BU
19/10/23	ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results	BU
02/10/23	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
29/09/23	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
29/09/23	ImmunoGen Inc. - ELAHERE Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FR-Positive Platinum-Resistant Ovarian Cancer	AQ
28/09/23	ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer	BU
18/09/23	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
18/09/23	ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer	BU